Literature DB >> 15262102

The cervical cancer epidemic that screening has prevented in the UK.

Julian Peto1, Clare Gilham, Olivia Fletcher, Fiona E Matthews.   

Abstract

BACKGROUND: Recent reports suggest that the reduction in mortality achieved by the UK national cervical screening programme is too small to justify its financial and psychosocial costs, except perhaps in a few high-risk women.
METHODS: We analysed trends in mortality before 1988, when the British national screening programme was launched, to estimate what future trends in cervical cancer mortality would have been without any screening.
FINDINGS: Cervical cancer mortality in England and Wales in women younger than 35 years rose three-fold from 1967 to 1987. By 1988, incidence in this age-range was among the highest in the world despite substantial opportunistic screening. Since national screening was started in 1988, this rising trend has been reversed.
INTERPRETATION: Cervical screening has prevented an epidemic that would have killed about one in 65 of all British women born since 1950 and culminated in about 6000 deaths per year in this country. However, these estimates are subject to substantial uncertainty, particularly in relation to the effects of oral contraceptives and changes in sexual behaviour. 80% or more of these deaths (up to 5000 deaths per year) are likely to be prevented by screening, which means that about 100000 (one in 80) of the 8 million British women born between 1951 and 1970 will be saved from premature death by the cervical screening programme at a cost per life saved of about pound 36000. The birth cohort trends also provide strong evidence that the death rate throughout life is substantially lower in women who were first screened when they were younger.

Entities:  

Mesh:

Year:  2004        PMID: 15262102     DOI: 10.1016/S0140-6736(04)16674-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  184 in total

1.  The role of funding and policies on innovation in cancer drug development.

Authors:  P Kanavos; R Sullivan; G Lewison; W Schurer; S Eckhouse; Z Vlachopioti
Journal:  Ecancermedicalscience       Date:  2010-02-03

2.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

3.  Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies.

Authors:  Rosa Legood; Alastair Gray; Jane Wolstenholme; Sue Moss
Journal:  BMJ       Date:  2006-01-06

4.  Cervical cancer, human papillomavirus, and vaccination.

Authors:  Catherine M Lowndes; O Noel Gill
Journal:  BMJ       Date:  2005-10-22

5.  The war on cancer: a report from the front lines.

Authors:  Gavin Melmed
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-10

6.  Human papillomavirus vaccine: a boon or curse.

Authors:  Sumit Chawla; Inderjeet Singh; Rambilas Jain; Bharti Mehta; Sneh Kumari; Soumya Swaroop Sahoo
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  Interventions for encouraging sexual behaviours intended to prevent cervical cancer.

Authors:  Jonathan P Shepherd; Geoff K Frampton; Petra Harris
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

8.  Reducing the Excess Burden of Cervical Cancer Among Latinas: Translating Science into Health Promotion Initiatives.

Authors:  Lourdes Baezconde-Garbanati; Sheila T Murphy; Meghan Bridgid Moran; Victoria K Cortessis
Journal:  Calif J Health Promot       Date:  2013

9.  "Drivers" of translational cancer epidemiology in the 21st century: needs and opportunities.

Authors:  Tram Kim Lam; Margaret Spitz; Sheri D Schully; Muin J Khoury
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-01-15       Impact factor: 4.254

10.  Young women's constructions of the HPV vaccine: a cross-cultural, qualitative study in Scotland, Spain, Serbia and Bulgaria.

Authors:  Carol Gray Brunton; Ingeborg Farver; Moritz Jäger; Anita Lenneis; Kadi Parve; Dina Patarcic; Dafina Petrova; Rhona Hogg; Catriona Kennedy; Rocio Garcia-Retamero; Irina Todorova
Journal:  Int J Behav Med       Date:  2014-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.